{"id":3436,"date":"2026-02-04T15:15:37","date_gmt":"2026-02-04T15:15:37","guid":{"rendered":"https:\/\/tradertideinsights.com\/?p=3436"},"modified":"2026-02-04T15:15:37","modified_gmt":"2026-02-04T15:15:37","slug":"eli-lilly-beats-earnings-lifts-outlook-on-booming-zepbound-and-mounjaro-sales","status":"publish","type":"post","link":"https:\/\/tradertideinsights.com\/?p=3436","title":{"rendered":"Eli Lilly beats earnings, lifts outlook on booming Zepbound and Mounjaro sales"},"content":{"rendered":"
<\/div>\n

Eli Lilly reported stronger-than-expected fourth-quarter earnings and issued robust guidance for the coming year, as soaring demand for its GLP-1 drugs reaffirmed its dominance in the global weight-loss drugs market.<\/p>\n

The US pharmaceutical giant posted net income of $6.64 billion<\/a>, or $7.39 a share, up from $4.41 billion, or $4.88 a share, a year earlier.<\/p>\n

Adjusted earnings came in at $7.54 a share, comfortably ahead of analysts\u2019 expectations of $6.91 a share, according to FactSet.<\/p>\n

Revenue rose 43% to $19.29 billion, beating Wall Street estimates of $17.94 billion. <\/p>\n

The surge was driven largely by a 46% increase in sales volume, partly offset by a 5% decline in realised prices.<\/p>\n

Eli Lilly’s share price surged by more than 8% during premarket trading on Tuesday on the back of the solid earnings announcement. <\/p>\n

Explosive growth in GLP-1 drug sales<\/h2>\n

The results were propelled by soaring demand for Lilly\u2019s blockbuster GLP-1 drugs, Mounjaro and Zepbound, which are used for diabetes and weight management. <\/p>\n

Both products recorded more than double the sales of the previous year.<\/p>\n

Mounjaro generated $7.41 billion in revenue in the quarter, up from $3.5 billion a year earlier, while Zepbound posted $4.26 billion in sales, up from $1.9 billion. <\/p>\n

Together, the two drugs have become the primary growth engine for the company, reflecting the rapid expansion of the global obesity and diabetes treatment market.<\/p>\n

Lilly\u2019s tirzepatide franchise, marketed as Mounjaro and Zepbound, has helped the company consolidate its position as a leader in the weight-loss drug segment, which has become one of the most lucrative areas of the pharmaceutical industry.<\/p>\n

Guidance signals continued momentum<\/h2>\n

Lilly forecast 2026 revenue of $80 billion to $83 billion and earnings of $33.50 to $35 a share, well above analysts\u2019 expectations of $77.64 billion in revenue and $32.47 a share in earnings.<\/p>\n

At the midpoint of its forecast, the company expects sales to grow by about 25% this year, signalling continued momentum despite mounting pricing pressure and intensifying competition.<\/p>\n

The guidance marks a sharp contrast with rival Novo Nordisk, which warned earlier this week that its sales and profit could fall by as much as 13% this year.<\/a><\/p>\n

Novo cited declining US prices and the expiry of exclusivity for some of its blockbuster drugs in key international markets.<\/p>\n

Pricing pressure looms large<\/h2>\n

Despite its strong outlook, Lilly acknowledged that it faces significant headwinds from falling drug prices. <\/p>\n

The company said global pricing could decline by a low- to mid-teens percentage, driven by multiple factors including lower Medicaid pricing, discounted direct-to-consumer rates for Zepbound and broader policy changes.<\/p>\n

Both Lilly and Novo recently struck landmark agreements with the Trump administration to cut the cost of obesity and diabetes drugs for Medicare and Medicaid beneficiaries from 2026. <\/p>\n

Under the deals, the companies also agreed to offer discounted prices directly to consumers through a planned government-backed platform, TrumpRx.<\/p>\n

In return, the companies will receive a three-year exemption from tariffs. <\/p>\n

While the agreements are expected to expand access and boost prescription volumes over time, they are likely to weigh on overall revenue growth.<\/p>\n

Race to launch next-generation weight-loss drugs<\/h2>\n

Lilly is preparing to launch a new oral weight-loss drug, orforglipron, which could further transform the market. <\/p>\n

Analysts believe the pill format could attract patients who are reluctant to use injectable treatments, potentially driving even higher demand than existing products.<\/p>\n

The company said it expects to launch the drug in the second quarter, pending regulatory approval in the United States. <\/p>\n

Lilly has also submitted regulatory filings for orforglipron in Japan and the European Union, signalling its ambition to secure a global footprint in oral GLP-1 treatments.<\/p>\n

Market leadership under pressure<\/h2>\n

At the same time, competition is intensifying as rivals explore more convenient drug delivery methods, including once-monthly injections and oral therapies. <\/p>\n

Novo Nordisk is preparing for the US launch of its own Wegovy pill, raising the stakes in the battle for market share.<\/p>\n

Lilly\u2019s share of the US obesity and diabetes drug market rose to 60.5% in the fourth quarter, up 2.6 percentage points from the previous quarter, while Novo\u2019s share stood at 39.1%. <\/p>\n

The figures highlight Lilly\u2019s current dominance but also the fragility of leadership in a fast-evolving market.<\/p>\n

As the global appetite for weight-loss drugs continues to grow, investors are increasingly focused on whether pharmaceutical companies can sustain growth amid falling prices, regulatory scrutiny and technological innovation.<\/p>\n

Lilly\u2019s latest results suggest that, for now, demand remains strong enough to offset these pressures. <\/p>\n

But the coming year is likely to test whether the company can defend its lead as the race for the next generation of weight-loss treatments accelerates.<\/p>\n

The post Eli Lilly beats earnings, lifts outlook on booming Zepbound and Mounjaro sales<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly reported stronger-than-expected fourth-quarter earnings and issued robust guidance for the coming year, as soaring demand for its GLP-1 drugs reaffirmed its dominance in the global weight-loss drugs market.The US pharmaceutical giant posted net income of $6.64 billion, or $7.39 a share, up from $4.41 billion, or $4.88 a share, a year earlier.Adjusted earnings…<\/p>\n","protected":false},"author":1,"featured_media":3437,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3436"}],"version-history":[{"count":0,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3436\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/media\/3437"}],"wp:attachment":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}